LELaura Esteban-Burgos

Laura Esteban-Burgos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Esteban-Burgos has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia in Spain: A Retrospective, Cross-Sectional Database Study

    by José-Ángel Hernández-Rivas, Lucrecia Yáñez San Segundo, Fátima de la Cruz Vicente, Laura Esteban-Burgos, Rocío Varea, Alberto Molero, Silvia Díaz-Cerezo, Raúl Córdoba Mascuñano

    Background/Objectives: This study describes demographic and clinical characteristics and treatment patterns (including sequencing) in patients with chronic lymphocytic leukemia (CLL) in Spain. Methods: A retrospective, multicenter, cross-sectional study analyzed 1128 adults with CLL receiving treatment in Spain (2022–2023), using two IQVIA databases. Descriptive statistics were applied. Results: Overall, 71.2% of patients were aged >65 years, 59.9% were male, and 86.1% had an ECOG performance status of 0–1. Common comorbidities included diabetes (25.3%) and cardiac dysfunction/atrial fibrillation (23.1%). More than 98% were tested for del(17p)/TP53 and IGHV mutation status. Covalent BTK inhibitors (cBTKis) predominated across treatment lines (first line: 81%; second: 67%; ≥third: 53%), with ibrutinib most frequent in every line (52%, 46%, and 26%, respectively). Venetoclax-based regimens ranked second (first: 15%; second: 30%; ≥third: 45%). In the first line, cBTKi use was highest among patients with del(17p)/TP53 mutations (92.5%). In the second line, 75% of prior cBTKi users switched to venetoclax-based therapy, while 85% without prior cBTKi received it. Disease progression and adverse effects were the main reasons for cBTKi discontinuation. Conclusions: In Spain, cBTKis predominate in CLL management. Findings indicate high uptake of genetic testing and treatment patterns broadly consistent with contemporary guidelines and highlight the importance of personalised strategies that consider high-risk genetic markers and patient comorbidities.

  • Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    by Laura Esteban-Burgos, Haiyun Wang, Patricia Nieto, Jie Zheng, Carmen Blanco-Aparicio, Carmen Varela, Gonzalo Gómez-López, Fernando Fernández-García, Manuel Sanclemente, Carmen Guerra, et al.

    Significance: So far, no targeted therapy has been approved for KRAS mutant tumors. We report that combined genetic inactivation of CDK4 and RAF1 in advanced KRAS/p53 mutant lung tumors leads to effective tumor regression without inducing significant toxicities. In spite of this therapeutic response, CDK4/RAF1-resistant cells appeared. We have identified and pharmacologically validated two independent resistance mechanisms involving hypermethylation of tumor-suppressor genes and activation of the PI3K pathway.


  • Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

    by María Teresa Blasco, Carolina Navas, Guillermo Martín-Serrano, Osvaldo Graña-Castro, Carmen G. Lechuga, Laura Martín-Díaz, Magdolna Djurec, Jing Li, Lucia Morales-Cacho, Laura Esteban-Burgos, et al.


  • c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling

    by Manuel Sanclemente, Sarah Francoz, Laura Esteban-Burgos, Emilie Bousquet-Mur, Magdolna Djurec, Pedro P. Lopez-Casas, Manuel Hidalgo, Carmen Guerra, Matthias Drosten, Monica Musteanu, et al.


  • A Braf kinase-inactive mutant induces lung adenocarcinoma

    by Patricia Nieto, Chiara Ambrogio, Laura Esteban-Burgos, Gonzalo Gómez-López, María Teresa Blasco, Zhan Yao, Richard Marais, Neal Rosen, Roberto Chiarle, David G. Pisano, et al.

    Kinase-inactive Braf mutants can initiate the development of lung adenocarcinoma in mice; co-expression of activated Kras enhances tumour initiation and progression, and wild-type Braf is required to sustain tumorigenesis. Mutant alleles of the kinase BRAF have been identified in human tumours, some of which have activated catalytic functions whereas others have impaired or absent kinase activity. Here David Santamaría and colleagues show that kinase-inactive BRAF mutants can initiate the development of lung adenocarcinoma in mice. Co-expression of activated K-Ras enhances tumour initiation and progression, and wild-type B-Raf is required to sustain tumorigenesis. Their results also illustrate that signal intensity of the MAP kinase pathway is important in determining K-Ras driven lung tumorigenesis. Elsewhere in this issue, Neal Rosen and colleagues show that hypoactive BRAF mutants bind more tightly to RAS and require coexistent mechanisms for RAS activation in tumours in order to function. The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies. Yet these tumours harbour a number of alterations without obvious oncogenic function including BRAF-inactivating mutations. Inactivating BRAF mutants in lung predominate over the activating V600E mutant that is frequently observed in other tumour types1. Here we demonstrate that the expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis. Moreover, inactivating BRAF mutations have also been identified in a subset of KRAS-driven human lung tumours. Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity2,3, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas. We also report a key role for the wild-type Braf kinase in sustaining Kras(G12V)/Braf(D631A)-driven tumours. Ablation of the wild-type Braf allele prevents the development of lung adenocarcinoma by inducing a further increase in MAPK signalling that results in oncogenic toxicity; this effect can be abolished by pharmacological inhibition of Mek to restore tumour growth. However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions. These observations indicate that the signal intensity of the MAPK pathway is a critical determinant not only in tumour development, but also in dictating the nature of the cancer-initiating cell and ultimately the resulting tumour phenotype.


  • Chronic Lymphocytic Leukemia: A Paradigm of Innate Immune Cross-Tolerance

    by Teresa Jurado-Camino, Raúl Córdoba, Laura Esteban-Burgos, Enrique Hernández-Jiménez, Victor Toledano, Jose-Angel Hernandez-Rivas, Elena Ruiz-Sainz, Teresa Cobo, María Siliceo, Rebeca Perez de Diego, et al.

    Infections are a significant cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). The pathogenesis of infections is multifactorial and includes hypogammaglobulinemia, conventional therapy with alkylating drugs, and recently, purine analogs and mAb-associated T cells. Patients without these risk factors also suffer from infections, although the mechanism remains unknown. In a cohort of 70 patients with CLL, we demonstrated that their monocytes were locked into a refractory state and were unable to mount a classic inflammatory response to pathogens. In addition, they exhibited the primary features of endotoxin tolerance, including low cytokine production, high phagocytic activity, and impaired Ag presentation. The involvement of miR-146a in this phenomenon was suspected. We found miR-146a target genes, such as IRAK1 and TRAF6, were manifestly downregulated. Our study provides a new explanation for infections in patients with CLL and describes a cross-tolerance between endotoxins and tumors.


  • Open Access

    NFκB2/p100 Is a Key Factor for Endotoxin Tolerance in Human Monocytes: A Demonstration Using Primary Human Monocytes from Patients with Sepsis

    by Carolina Cubillos-Zapata, Enrique Hernández-Jiménez, Víctor Toledano, Laura Esteban-Burgos, Irene Fernández-Ruíz, Vanesa Gómez-Piña, Carlos del Fresno, María Siliceo, Patricia Prieto-Chinchiña, Rebeca Pérez de Diego, et al.

    Endotoxin tolerance (ET) is a state of reduced responsiveness to endotoxin stimulation after a primary bacterial insult. This phenomenon has been described in several pathologies, including sepsis, in which an endotoxin challenge results in reduced cytokine production. In this study, we show that the NFκ L chain enhancer of activated B cells 2 (NFκB2)/p100 was overexpressed and accumulated in a well-established in vitro human monocyte model of ET. The p100 accumulation in these cells inversely correlated with the inflammatory response after LPS stimulation. Knocking down NFκB2/p100 using small interfering RNA in human monocytes further indicated that p100 expression is a crucial factor in the progression of ET. The monocytes derived from patients with sepsis had high levels of p100, and a downregulation of NFκB2/p100 in these septic monocytes reversed their ET status.


  • Open Access

    Mitochondrial DAMPs Induce Endotoxin Tolerance in Human Monocytes: An Observation in Patients with Myocardial Infarction

    by Irene Fernández-Ruiz, Francisco Arnalich, Carolina Cubillos-Zapata, Enrique Hernández-Jiménez, Raúl Moreno-González, Víctor Toledano, María Fernández-Velasco, Maria T. Vallejo-Cremades, Laura Esteban-Burgos, Rebeca Pérez de Diego, et al.

    Monocyte exposure to mitochondrial Danger Associated Molecular Patterns (DAMPs), including mitochondrial DNA (mtDNA), induces a transient state in which these cells are refractory to further endotoxin stimulation. In this context, IRAK-M up-regulation and impaired p65 activity were observed. This phenomenon, termed endotoxin tolerance (ET), is characterized by decreased production of cytokines in response to the pro-inflammatory stimulus. We also show that monocytes isolated from patients with myocardial infarction (MI) exhibited high levels of circulating mtDNA, which correlated with ET status. Moreover, a significant incidence of infection was observed in those patients with a strong tolerant phenotype. The present data extend our current understanding of the implications of endotoxin tolerance. Furthermore, our data suggest that the levels of mitochondrial antigens in plasma, such as plasma mtDNA, should be useful as a marker of increased risk of susceptibility to nosocomial infections in MI and in other pathologies involving tissue damage.